编者按
第66届美国血液学会(ASH)将于2024年12月7~10日在美国圣迭戈(San Diego)盛大召开。作为全球血液学领域规模最大、涵盖最全面的国际学术盛会之一,每年吸引着成千上万名来自世界各地的专家学者,分享最前沿的血液学进展和突破性临床数据。日前,大会官网公布了入选摘要,引人瞩目的是,70+篇由中国学者主导的研究入选口头报告(Oral),创历史新高!这些研究成果不仅是血液学领域探索的最前沿标志,更彰显了中国在血液学研究版图上的坚实步伐与卓越贡献。本刊特此精心整理,带您领略中国血液学专家的非凡风采与卓越成就。
恶性血液肿瘤篇
PART.01
01
摘要号:38
标题:The TFG-ROS1 Fusion Is an Oncogenic Driver of Human Myeloid Leukemia
中文标题:TFG-ROS1融合是人类髓系白血病的一个致癌驱动因素
汇报人:Jie Sun(浙江大学医学院附属第一医院骨髓移植中心)汇报时间:Saturday, December 7, 2024: 9:45 AM汇报地点:Room 6A (San Diego Convention Center)
02
摘要号:89
标题:Targeted-Delivery Strategy of Engineered EV Functionalized By Anti-CD3/CD19 Bi-Specific T-Cell Engager in Treating B-Cell Malignancies
中文标题:抗CD3/CD19双特异性T细胞衔接器功能化EV治疗B细胞恶性肿瘤的靶向递送策略
汇报人:Xiuiu Yang(华中科技大学同济医学院同济医院血液科)汇报时间:Saturday, December 7, 2024: 10:30 AM汇报地点:Ballroom 20AB (San Diego Convention Center)
03
摘要号:91
标题:Rituximab, Lenalidomide, and Zanubrutinib (ZR2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma
中文标题:利妥昔单抗联合来那度胺和泽布替尼(ZR2)序贯CAR-T细胞疗法作为高危大B细胞淋巴瘤的一线治疗
汇报人:Mingming Zhang(浙江大学医学院附属第一医院骨髓移植中心)汇报时间:Saturday, December 7, 2024: 9:30 AM
汇报地点:Marriott Grand Ballroom 11-13(Marriott Marquis San Diego Marina)
04
摘要号:92
标题:IL-10 Expressing CD19 CAR-T Cells Induce Complete Remission and Improve Long-Term Protection in Relapsed or Refractory B-Cell Hematological Malignancies
中文标题:表达IL-10的CD19 CAR-T细胞诱导复发或难治性B细胞血液恶性肿瘤完全缓解并改善长期保护作用
汇报人:Jingjing Ren(深圳市莱芒生物科技有限公司)汇报时间:Saturday, December 7, 2024: 9:45 AM汇报地点:Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
05
摘要号:156
标题:Potent in Vitro and In Vivo Efficacy of Hdz-C123A, a GSPT1 Degrader-Antibody Conjugate Targeting CD123 in Acute Myeloid Leukemia
中文标题:靶向CD123的GSPT1降解抗体偶联物Hdz-C123A在急性髓系白血病中的体外和体内疗效
汇报人:Yu Guo(杭州和正医药有限公司)汇报时间:Saturday, December 7, 2024: 1:15 PM汇报地点:Room 33 (San Diego Convention Center)
06
摘要号:222
标题:Prospective Study of Avapritinib in Patients with Relapsed/Refractory or MRD-Positive Core-Binding Factor Acute Myeloid Leukemia with KIT Mutations中文标题:阿伐替尼治疗伴KIT突变的复发/难治性或MRD阳性核心结合因子急性髓系白血病患者的前瞻性研究
汇报人:Xueqing Dou(苏州大学附属第一医院)汇报时间:Saturday, December 7, 2024: 3:15 PM汇报地点:Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)
07
摘要号:270
标题:Safety and Efficacy of VA Combined with Modified BuCy Conditioning Regimen Followed By Allo-HSCT for High-Risk or Refractory/Relapsed Acute Lymphoblastic Leukemia : A Prospective, Single-Center, Single-Arm Clinical Trial
中文标题:VA联合改良BuCy预处理方案后行异基因造血干细胞移植治疗高危或难治/复发急性淋巴细胞白血病的安全性和有效性:一项前瞻性、单中心、单臂临床试验
汇报人:Xiaoqian Chen(苏州大学附属第一医院)
汇报时间:Saturday, December 7, 2024: 3:15 PM
汇报地点:Room 6CF(San Diego Convention Center)
08
摘要号:312
标题:Efficacy and Safety of Adding Blinatumomab to First-Line Treatment for Chinese Children with B-Cell Acute Lymphoblastic Leukemia
中文标题:中国儿童B细胞急性淋巴细胞白血病一线治疗中加用布林妥莫单抗的疗效和安全性
汇报人:Ruidong Zhang(首都医科大学附属北京儿童医院血液学中心)汇报时间:Saturday, December 7, 2024: 5:15 PM汇报地点:Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina
09
摘要号:328
标题:Integrative Multi-Omics Analyses Identify a High-Risk Subgroup of Patients with Poor Prognosis in t(8;21) Acute Myeloid Leukemia
中文标题:综合多组学分析鉴定出t(8;21)急性髓系白血病中预后不良的高危亚组
汇报人:Yu Liu [中国医学科学院血液病医院(中国医学科学院血液学研究所)]汇报时间:Saturday, December 7, 2024: 4:45 PM汇报地点:Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
10
摘要号:345
标题:Mitochondrial Transcriptional-Translational Conflict Contributes to Defective Erythropoiesis and Disease Progression in Splicing Factor Mutant Myelodysplastic Syndromes
中文标题:线粒体转录翻译冲突导致剪接因子突变型骨髓增生异常综合征的红细胞生成缺陷和疾病进展
汇报人:Qiaoli Li [中国医学科学院血液病医院(中国医学科学院血液学研究所)]汇报时间:Saturday, December 7, 2024: 4:30 PM汇报地点:Ballroom 20CD (San Diego Convention Center)
11
摘要号:372
标题:Modified Dual CLL1-CD15 and CLL1-CD16 Icar-T Cells for Mitigating Granulocytopenia Toxicities in the Treatment of Acute Myeloid Leukemia
中文标题:改良型双靶点CLL1-CD15和CLL1-CD16 Icar-T细胞用于减轻急性髓系白血病治疗中的粒细胞减少毒性
汇报人:Rui Zhang(天津市第一中心医院)
汇报时间:Saturday, December 7, 2024: 5:15 PM
汇报地点:Grand Hall C(Manchester Grand Hyatt San Diego)
12
摘要号:452
标题:Spatial Architecture of Immune Microenvironment Orchestrating Anti-Lymphoma Immunity and the Response to Immunochemotherapy in EBV+ Diffused Large B Cell Lymphoma Revealed By Imaging Mass Cytometry and Spatial
中文标题:通过成像质谱流式细胞术和空间转录组揭示EBV+弥漫性大B细胞淋巴瘤中调控抗淋巴瘤免疫和免疫化疗反应的免疫微环境空间结构
汇报人:Zhijuan Lin(厦门大学附属第一医院血液科)汇报时间:Sunday, December 8, 2024: 9:45 AM汇报地点:Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
13
摘要号:477
标题:Safety and Efficacy of Tgrx-678, a Potent BCR::ABL1 allosteric Inhibitor, in Patients with Tyrosine Kinase Inhibitor Resistant and/or Intolerant Chronic Myeloid Leukemia: Updated Results of Phase 1 Study Tgrx-678 -1001
中文标题:强效BCR::ABL1变构抑制剂Tgrx-678在治疗酪氨酸激酶抑制剂耐药和/或不耐受慢性髓系白血病患者中的安全性和有效性:I期研究Tgrx-678-1001的更新结果
汇报人:江倩(北京大学人民医院)汇报时间:Sunday, December 8, 2024: 10:00 AM汇报地点:Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
14
摘要号:480
标题:Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)
中文标题:奥瑞巴替尼作为慢性期慢性髓系白血病(CP-CML)患者二线(2L)治疗药物
汇报人:Weiming Li(华中科技大学同济医学院附属协和医院血液科)汇报时间:Sunday, December 8, 2024: 10:45 AM汇报地点:Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
15
摘要号:484
标题:Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study
中文标题:Rovadicitinib治疗难治、复发性或对Ruxolitinib不耐受的骨髓纤维化患者:一项单臂、多中心、开放标签、Ib期研究
汇报人:常春康(上海交通大学医学院上海第六人民医院血液科)汇报时间:Sunday, December 8, 2024: 10:15 AM汇报地点:Grand Hall C (Manchester Grand Hyatt San Diego)
16
摘要号:486
标题:First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis
中文标题:新一代JAK2/FLT3抑制剂马来酸氟诺替尼治疗骨髓纤维化的首个人体I/IIa期安全性和有效性研究
汇报人:Lijuan Chen(四川大学华西医院血液科)汇报时间:Sunday, December 8, 2024: 10:45 AM汇报地点:Grand Hall C (Manchester Grand Hyatt San Diego)
17
摘要号:576
标题:Clinical Implications of CSF-Ctdna Positivity in Newly Diagnosed Diffuse Large B Cell Lymphoma in a Large Cohort
中文标题:大型队列中新诊断的弥漫性大B细胞淋巴瘤患者脑脊液循环肿瘤DNA(CSF-ctDNA)阳性的临床意义
汇报人:梁金花 [南京医科大学第一附属医院(江苏省人民医院)血液科]汇报时间:Sunday, December 8, 2024: 1:15 PM汇报地点:Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
18
摘要号:599
标题:Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Improved Prognosis for Advanced NK/T Cell Lymphoma
中文标题:清髓性异基因造血干细胞移植可改善晚期NK/T细胞淋巴瘤患者的预后
汇报人:李智慧(北京高博博仁医院移植科)汇报时间:Sunday, December 8, 2024: 1:00 PM汇报地点:Room 11 (San Diego Convention Center)
19
摘要号:663
标题:Decitabine Plus All-Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled TrialClinically Relevant Abstract
中文标题:地西他滨联合全反式维甲酸对比地西他滨单药治疗伴有过多原始细胞的骨髓增生异常综合征:一项多中心随机对照试验
汇报人:佟红艳(浙江大学医学院附属第一医院血液科)汇报时间:Sunday, December 8, 2024: 5:00 PM汇报地点:Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
20
摘要号:681
标题:Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia
中文标题:双顺反子CD19/CD22 CAR T细胞疗法在儿童B细胞急性淋巴细胞白血病中的安全性和有效性
汇报人:Hua Zhang [SPH生物治疗(上海)有限公司]汇报时间:Sunday, December 8, 2024: 5:00 PM汇报地点:Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
21
摘要号:696
标题:Haploidentical Peripheral Blood Stem Cell Combined with Bone Marrow or Unrelated Cord Blood As Grafts for Acute Leukemia/Myelodysplastic Syndrome: An Open-Label, Multicenter, Randomized, Phase 3 Trial
中文标题:单倍体相合外周血干细胞联合骨髓或无关脐带血作为急性白血病/骨髓增生异常综合征移植供体的开放标签、多中心、随机、III期试验
汇报人:Sijian Yu(南方医科大学南方医院)汇报时间:Sunday, December 8, 2024: 5:45 PM汇报地点:Room 6A (San Diego Convention Center)
22
摘要号:832
标题:TENT5C As a Target of Chromatin Remodeler SMARCA2 Participates BTK Inhibitor Resistance in Mantle Cell Lymphoma By Regulating ATP Metabolism
中文标题:TENT5C作为染色质重塑剂SMARCA2的靶点,通过调节ATP代谢参与套细胞淋巴瘤对BTK抑制剂的耐药
汇报人:Yuting Yan [中国医学科学院血液病医院(中国医学科学院血液学研究所)]汇报时间:Monday, December 9, 2024: 3:30 PM汇报地点:Ballroom 20CD (San Diego Convention Center)
23
摘要号:833
标题:ST6GALNAC4 Promotes Diffuse Large B-Cell Lymphoma Progression Via Mediating Sialylation of Bmpr-1B at Thr24m
中文标题:ST6GALNAC4通过介导BMPR-1B第24位苏氨酸的唾液酸化促进弥漫性大B细胞淋巴瘤进展
汇报人:Yu Zhang(山东第一医科大学附属山东省医院血液科)汇报时间:Monday, December 9, 2024: 3:45 PM汇报地点:Ballroom 20CD (San Diego Convention Center)
24
摘要号:836
标题:Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial
中文标题:维奈托克联合HAG方案治疗新诊断的早期前体T细胞急性淋巴细胞白血病:一项前瞻性、多中心、II期试验
汇报人:Shanshan Suo(浙江大学医学院附属第一医院血液科)汇报时间:Monday, December 9, 2024: 3:00 PM汇报地点:Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
25
摘要号:839
标题:Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial
中文标题:Tucidinostat联合儿童启发化疗作为新诊断的早期前体T细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤的一线治疗:一项开放标签、单臂、II期试验
汇报人:Jieping Lin(南方医科大学南方医院血液科)汇报时间:Monday, December 9, 2024: 3:45 PM汇报地点:Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
26
摘要号:843
标题:The Mutated of KRAS gene Determine the Fate of KMT2A-Rearranged AML Patients
中文标题:KRAS基因突变决定KMT2A重排急性髓系白血病患者的命运
汇报人:吴一波(浙江大学医学院附属第一医院骨髓移植中心)汇报时间:Monday, December 9, 2024: 3:15 PM汇报地点:Grand Hall C (Manchester Grand Hyatt San Diego)
27
摘要号:874
标题:CD38 Overexpressed Monocytes Play a Critical Role in the Fibrogenesis in Myeloproliferative Neoplasms and Can be Used As a Therapeutic Target to Ameliorate Fibrosis
中文标题:CD38高表达的单核细胞在骨髓增殖性肿瘤纤维化中起关键作用,并可作为改善纤维化的治疗靶点
汇报人:Bing Li [中国医学科学院血液病医院(中国医学科学院血液学研究所)]汇报时间:Monday, December 9, 2024: 3:30 PM汇报地点:Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego
28
摘要号:904
标题:CD33 Antibody-Modified Nanoparticles Encapsulated IL-15 Induce ISG15 to Promote MHC I Expression in Leukemia Cells Via Innate Immunity Pathway Inducing Graft-Versus-Leukemia without Aggravating Graft-Versus-Host Disease
中文标题:包裹IL-15的CD33抗体修饰的纳米粒子通过先天免疫途径诱导ISG15促进白血病细胞中MHC I的表达,诱导移植物抗白血病,而不会加重移植物抗宿主病
汇报人:Ruowen Wei(华中科技大学同济医学院附属协和医院血液研究所)汇报时间:Monday, December 9, 2024: 3:30 PM汇报地点:Room 6B (San Diego Convention Center)
29
摘要号:921
标题:A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/Lbl: A Phase I Clinical Trial
中文标题:新一代抗CD7通用CAR-T疗法治疗复发或难治性CD7阳性T细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤患者的I期临床试验
汇报人:胡永仙(浙江大学医学中心良渚实验室)汇报时间:Monday, December 9, 2024: 3:15 PM汇报地点:Hall B (San Diego Convention Center)
30
摘要号:923
标题:A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease
中文标题:一项前瞻性研究者发起的BCMA/CD19双靶点CAR T细胞疗法治疗复发/难治性多发性骨髓瘤(包括髓外病变患者)的I/II期研究
汇报人:Hua Jiang(同济大学医学院上海第四人民医院)汇报时间:Monday, December 9, 2024: 3:45 PM汇报地点:Hall B (San Diego Convention Center)
31
摘要号:956
标题:A Highly Selective and Orally Bioavailable CK1α Molecular Glue Degrader Targets B-Cell Lymphoma Cells
中文标题:一种高选择性和口服生物可利用的CK1α分子胶降解剂靶向B细胞淋巴瘤细胞
汇报人:Ran Kong(山东大学山东省医院血液科)汇报时间:Monday, December 9, 2024: 4:45 PM汇报地点:Ballroom 20CD (San Diego Convention Center)
32
摘要号:958
标题:KPT-330 Combined with Radiation Therapy: Effective Central Nervous System Lymphoma Treatment with Reduced Neurotoxicity
中文标题:KPT-330联合放疗有效治疗中枢神经系统淋巴瘤并降低神经毒性
汇报人:Bingzong Li(苏州大学附属第二医院)汇报时间:Monday, December 9, 2024: 5:15 PM汇报地点:Ballroom 20CD (San Diego Convention Center)
33
摘要号:960
标题:CD93+ Myeloid Cells Suppress T-Cell-Mediated Anti-Tumor Immunity
中文标题:CD93+髓系细胞抑制T细胞介导的抗肿瘤免疫
汇报人:Hui Yu(北京大学肿瘤医院)汇报时间:Monday, December 9, 2024: 5:45 PM汇报地点:Ballroom 20CD (San Diego Convention Center)
34
摘要号:964
标题:CD7 CAR T-Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Retrospective Study
中文标题:CD7 CAR-T细胞疗法治疗复发或难治性T细胞急性淋巴细胞白血病的回顾性研究
汇报人:潘静(北京高博医院)汇报时间:Monday, December 9, 2024: 5:15 PM汇报地点:Marriott Grand Ballroom 5-6 (Marriott Marquis San Diego Marina)
35
摘要号:971
标题:Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial
中文标题:维奈托克联合地西他滨与标准强化化疗作为新诊断急性髓系白血病诱导治疗的比较:一项多中心、随机、IIb期试验的更新结果
汇报人:Jing Lu(苏州大学附属第一医院)汇报时间:Monday, December 9, 2024: 5:30 PM汇报地点:Grand Hall B (Manchester Grand Hyatt San Diego)
36
摘要号:972
标题:High-Dose Cytarabine with Idarubicin Versus High-Dose Cytarabine within First Consolidation for Acute Myeloid Leukemia in First Complete Remission: An Open-Label, Multicenter, Randomized, Phase 3 Trial
中文标题:首次完全缓解期急性髓系白血病患者首次巩固治疗中高剂量阿糖胞苷联合伊达比星对比高剂量阿糖胞苷:一项开放标签、多中心、随机、III期试验
汇报人:Zinan Feng(南方医科大学南方医院血液科)汇报时间:Monday, December 9, 2024: 5:45 PM汇报地点:Grand Hall B (Manchester Grand Hyatt San Diego)
37
摘要号:977
标题:Faecalibacterium Prausnitzii Confers a Protective Effect Against the Development of NKTCL
中文标题:Prausnitzii粪杆菌对NKTCL的发展具有保护作用
汇报人:Zhuangzhuang Shi(郑州大学第一附属医院)汇报时间:Monday, December 9, 2024: 5:30 PM汇报地点:Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
38
摘要号:986
标题:Final Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
中文标题:泽布替尼联合来那度胺治疗复发/难治性弥漫大 B 细胞淋巴瘤患者的I期临床研究最终分析
汇报人:宋拯(天津医科大学肿瘤医院)汇报时间:Monday, December 9, 2024: 4:45 PM汇报地点:Pacific Ballroom Salons 18-19 (Marriott Marquis San Diego Marina)
39
摘要号:1002
标题:The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: The Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study
中文标题:塞利尼索联合芦可替尼治疗经芦可替尼治疗的骨髓纤维化患者的疗效和安全性:一项前瞻性、开放标签、多中心、平行队列、II期研究的期中分析
汇报人:段明辉 [中国医学科学院北京协和医院(北京协和医院)]汇报时间:Monday, December 9, 2024: 5:45 PM汇报地点:Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)
40
摘要号:1028
标题:A Single-Center, Single-Arm, Phase I Clinical Trial of Anti-BCMA/GPRC5D Bispecific CAR T-Cells in Patients with Refractory and Relapsed Multiple Myeloma with Extramedullary Disease
中文标题:一项单中心、单臂、I期临床试验:抗BCMA/GPRC5D双特异性CAR-T细胞治疗伴有髓外病变的复发/难治性多发性骨髓瘤患者
汇报人:Ling Qiu(中国人民解放军西部战区总医院血液科)汇报时间:Monday, December 9, 2024: 4:45 PM汇报地点:Pacific Ballroom Salons 24-26 (Marriott Marquis San Diego Marina)
41
摘要号:1049
标题:Mini-Dosed Blinatumomab Maintenance Therapy Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute B-Cell Lymphoblastic Leukemia
中文标题:异基因造血干细胞移植后微小剂量Blinatumomab维持治疗急性B细胞淋巴细胞白血病
汇报人:Jie Ji(四川大学华西医院)汇报时间:Monday, December 9, 2024: 5:30 PM汇报地点:Room 6A (San Diego Convention Center)
42
摘要号:1050
标题:Updated Results from a Phase II Clinical Trial Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia
中文标题:高危急性髓系白血病患者异基因造血干细胞移植后地西他滨和西达本胺维持治疗的II期临床试验安全性和有效性的更新结果
汇报人:Rui Huang(南方医科大学珠江医院)汇报时间:Monday, December 9, 2024: 5:45 PM汇报地点:Room 6A (San Diego Convention Center)
非恶性血液疾病篇
PART.02
01
摘要号:12
标题:Rbm38 Regulates Heme Biosynthesis Via Fine-Tuning the RNA Alternative Splicing, Stability and Translation of Porphyrin Metabolic Enzyme Gene Ferrochelatase (Fech)
中文标题:Rbm38通过精细调节卟啉代谢酶基因铁螯合酶(Fech)的RNA可变剪接、稳定性和翻译来调控血红素生物合成
汇报人:Yang Mei(湖南大学附属湘潭中心医院)汇报时间:Saturday, December 7, 2024: 10:45 AM汇报地点:Room 29 (San Diego Convention Center)
02
摘要号:30
标题:Clec16a-Mediated Mitophagy Modulates Zebrafish Definitive Hematopoiesis
中文标题:Clec16a介导的线粒体自噬调节斑马鱼确定性造血
汇报人:Shuyang Cai(上海中医药大学上海市中医医院)汇报时间:Saturday, December 7, 2024: 10:45 AM汇报地点:Room 6DE (San Diego Convention Center)
03
摘要号:97
标题:JAK/Rock Inhibitor Rovadicitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease updated Results of Multicenter, Phase 1b/2a Trial
中文标题:JAK/ROCK抑制剂Rovadicitinib治疗糖皮质激素难治性或依赖性慢性移植物抗宿主病:多中心Ⅰb/Ⅱa期试验的最新结果
汇报人:赵妍敏(浙江大学医学院附属第一医院骨髓移植中心)汇报时间:Saturday, December 7, 2024: 9:30 AM汇报地点:Ballroom 20CD (San Diego Convention Center)
04
摘要号:99
标题:A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment
中文标题:一项评估匹米替尼(ABSK021)在经1种或多种全身治疗后的慢性移植物抗宿主病(cGvHD)中疗效和安全性的II期研究
汇报人:吴德沛( 苏州大学附属第一医院)汇报时间:Saturday, December 7, 2024: 10:00 AM汇报地点:Ballroom 20CD (San Diego Convention Center)
05
摘要号:101
标题:Multiomic Analyses Uncover Immune Signatures of Steroid-Refractory Graft-Versus-Host Disease
中文标题:多组学分析揭示类固醇难治性移植物抗宿主病的免疫特征
汇报人:Zengkai Pan(上海交通大学医学院附属瑞金医院)汇报时间:Saturday, December 7, 2024: 10:30 AM汇报地点:Ballroom 20CD (San Diego Convention Center)
06
摘要号:125
标题:Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases
中文标题:由TNFRSF13B变异调控的TACI异构体表达失衡促进EB病毒相关淋巴增殖性疾病的进展
汇报人:Xinyue Deng(华中科技大学同济医学院附属同济医院)汇报时间:Saturday, December 7, 2024: 1:00 PM汇报地点:Room 11 (San Diego Convention Center)
07
摘要号:150
标题:Efficient Generation of CAR-T By the First Coacervate-Based Gene Delivery System
中文标题:基于首个共聚体基因递送系统高效生成CAR-T细胞
汇报人:Peipei Zhu(西湖大学)汇报时间:Saturday, December 7, 2024: 1:15 PM汇报地点:Room 25 (San Diego Convention Center)
08
摘要号:164
标题:Reconstruction of Megaloblastic Anemia in a Novel Erythroblastic Island Humanized Mouse Model with Mature Circulating Human Red Blood Cells
中文标题:在具有成熟循环人红细胞的新型红系造血岛人源化小鼠模型中重建巨幼细胞性贫血
汇报人:Shuang Liu(南京大学医学院模型动物研究中心)汇报时间:Saturday, December 7, 2024: 2:15 PM汇报地点:Room 33 (San Diego Convention Center)
09
摘要号:192
标题:Exploring the Mechanism of Chromatin Spatial Structure Changes and Transcriptional Regulation in Age-Related Clonal Hematopoiesis Caused By DNMT3A Mutations Using Chromatin Capture Technology
中文标题:利用染色质捕获技术探索由DNMT3A突变引起的与年龄相关的克隆性造血中染色质空间结构变化及转录调控机制
汇报人:Yujun Dai(中山大学肿瘤防治中心)
汇报时间:Saturday, December 7, 2024: 3:15 PM
汇报地点:Grand Hall D (Manchester Grand Hyatt San Diego)
10
摘要号:263
标题:Targeting the Hypoxic Microenvironment in Cutaneous Chronic Graft-Versus-Host Disease through PI3K Inhibition
中文标题:通过PI3K抑制靶向皮肤慢性移植物抗宿主病的缺氧微环境
汇报人:Yuxi Xu(陆军军医大学新桥医院血液病医学中心)汇报时间:Saturday, December 7, 2024: 3:00 PM汇报地点:Room 6B (San Diego Convention Center)
11
摘要号:266
标题:Elevated Dosing of Recombinant Human Thrombopoietin Accelerates Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Dosage-Optimization, Controlled Clinical Study
中文标题:增加重组人血小板生成素剂量可加速异基因造血干细胞移植后血小板植入:一项前瞻性、剂量优化、对照临床研究
汇报人:Dan Feng [中国医学科学院血液病医院(中国医学科学院血液学研究所)]汇报时间:Saturday, December 7, 2024: 2:15 PM汇报地点:Room 6CF (San Diego Convention Center)
12
摘要号:268
标题:Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disorders after Allo-HSCT in the Era of Letermovir for Cytomegalovirus Prophylaxis
中文标题:在利特莫韦预防巨细胞病毒感染时代异基因造血干细胞移植后EB病毒再激活和移植后淋巴增殖性疾病
汇报人:Jingtao Huang(上海血液学研究所)汇报时间:Saturday, December 7, 2024: 2:45 PM汇报地点:Room 6CF (San Diego Convention Center)
13
摘要号:300
标题:Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical
中文标题:低分子肝素对蛋白S缺乏症患者妊娠结局的影响:一项前瞻性、随机对照II期临床研究
汇报人:Mengtong Zang(北京大学人民医院)汇报时间:Saturday, December 7, 2024: 5:15 PM汇报地点:Room 29 (San Diego Convention Center)
14
摘要号:304
标题:Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
中文标题:一线治疗重型再生障碍性贫血时,在免疫抑制疗法中添加海曲泊帕:一项随机、双盲、安慰剂对照的III期试验
汇报人:张凤奎 [中国医学科学院血液病医院(中国医学科学院血液学研究所)]
汇报时间:Saturday, December 7, 2024: 4:45 PM
汇报地点:Room 11 (San Diego Convention Center)
15
摘要号:378
标题:A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
中文标题:输血依赖性地中海贫血患者异基因造血干细胞移植的多中心临床试验
汇报人:Rongrong Liu(广西医科大学附属第一医院血液科)汇报时间:Saturday, December 7, 2024: 5:15 PM汇报地点:Room 6DE (San Diego Convention Center)
16
摘要号:420
标题:A Single-Cell Transcriptomic Atlas of Cytokine Storm in CAR-T Therapy, COVID-19, and SLE
中文标题:CAR-T疗法、COVID-19和系统性红斑狼疮中细胞因子风暴的单细胞转录组图谱
汇报人:Xia Li(浙江大学医学院附属第一医院骨髓移植中心)汇报时间:Sunday, December 8, 2024: 10:45 AM汇报地点:Grand Hall D (Manchester Grand Hyatt San Diego)
17
摘要号:425
标题:β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia
中文标题:β2-肾上腺素受体激动剂特布他林通过HMGB1调节免疫性血小板减少症中的巨噬细胞极化
汇报人:Qiuyu Guo(北京大学人民医院)汇报时间:Sunday, December 8, 2024: 10:30 AM汇报地点:Room 28 A-D (San Diego Convention Center)
18
摘要号:426
标题:Differentiation Route Generates Functional Biased Platelets and Responses Distinctly to Varying Physiological Demands
中文标题:分化途径产生功能偏倚的血小板,并对不同的生理需求产生不同的反应
汇报人:Jingkun Liu(中国国家生物信息中心)汇报时间:Sunday, December 8, 2024: 10:45 AM汇报地点:Room 28 A-D (San Diego Convention Center)
19
摘要号:437
标题:ERAD Activity Distinguishes the Functional Heterogeneity of Hematopoietic Stem Cells
中文标题:ERAD活性区分造血干细胞的功能异质性
汇报人:QinLu Peng(湖南省动物模型与分子医学重点实验室)汇报时间:Sunday, December 8, 2024: 10:30 AM汇报地点:Room 7 (San Diego Convention Center)
20
摘要号:438
标题:SNORD113-114 Cluster Maintains Hematopoietic Stem Cell Self-Renewal Via Orchestrating the Translation Machinery
中文标题:SNORD113-114基因簇通过协调翻译机制维持造血干细胞自我更新
汇报人:Hui Wang(浙江大学医学院附属第一医院骨髓移植中心)汇报时间:Sunday, December 8, 2024: 10:45 AM汇报地点:Room 7 (San Diego Convention Center)
21
摘要号:538
标题:Polycomb Repressive Complex 2 Regulates Differentiation-Stage-Specific Autophagy Gene Expression and Safeguards Normal Erythropoiesis
中文标题:多梳抑制复合体2调控分化阶段特异性的自噬基因表达并保障正常红细胞生成
汇报人:Jiazhuo Li(华南理工大学医学院附属第二医院)汇报时间:Sunday, December 8, 2024: 12:45 PM汇报地点:Room 6DE (San Diego Convention Center)
22
摘要号:539
标题:A Novel Role of LKB1 in Erythroblast Enucleation
中文标题:LKB1在红系细胞脱核中的新作用
汇报人:Yuanlin Xu [河南省肿瘤医院(郑州大学附属肿瘤医院)]
汇报时间:Sunday, December 8, 2024: 1:00 PM汇报地点:Room 6DE (San Diego Convention Center)
23
摘要号:562
标题:Procr+ Endothelial Progenitor Cells Modulate Adult Hematopoiesis and Microenvironment Homeostasis Via Notch Signaling
中文标题:Procr+内皮祖细胞通过Notch信号通路调节成人造血和微环境稳态
汇报人:Chang Xu [中国医学科学院血液病医院(中国医学科学院血液学研究所)]汇报时间:Sunday, December 8, 2024: 12:45 PM汇报地点:Room 7 (San Diego Convention Center)
24
摘要号:682
标题:CD19 CAR T-Cell Therapy in Refractory Autoimmune Hemolytic Anemia
中文标题:CD19 CAR T细胞疗法治疗难治性自身免疫性溶血性贫血
汇报人:Ruonan Li[中国医学科学院血液病医院(中国医学科学院血液学研究所)]汇报时间:Sunday, December 8, 2024: 5:15 PM汇报地点:Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
25
摘要号:683
标题:Sequential Infusion of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor T-Cells: A Promising Treatment Strategy for Refractory Immune-Mediated Platelet Transfusion Refractoriness
中文标题:序贯输注抗CD19和抗BCMA嵌合抗原受体T细胞:一种治疗难治性免疫介导的血小板输注无效的有前景的治疗策略
汇报人:Yunju Ma(苏州大学附属第一医院)汇报时间:Sunday, December 8, 2024: 5:30 PM汇报地点:Marriott Grand Ballroom 2-4 (Marriott Marquis San Diego Marina)
26
摘要号:690
标题:Parvovirus B19 Originates from Infected Hematopoietic Stem Cells Following Hematopoietic Stem Cell Transplantation
中文标题:细小病毒B19起源于造血干细胞移植后受感染的造血干细胞
汇报人:Xuying Pei(北京大学人民医院)汇报时间:Sunday, December 8, 2024: 5:45 PM汇报地点:Room 6B (San Diego Convention Center)
27
摘要号:711
标题:Preliminary Efficacy and Safety Results of TQB3473, a Novel Syk Inhibitor, in Adult Patients with Immune Thrombocytopenia (ITP)
中文标题:新型Syk抑制剂TQB3473治疗成人免疫性血小板减少症(ITP)的初步疗效和安全性结果
汇报人:周虎 [河南省肿瘤医院(郑州大学附属肿瘤医院)]汇报时间:Monday, December 9, 2024: 11:00 AM汇报地点:Room 29 (San Diego Convention Center)
28
摘要号:712
标题:Updated Outcome from Biomarker MSC-C5b-9-Guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial
中文标题:生物标志物MSC-C5b-9指导的全反式维甲酸治疗难治/复发免疫性血小板减少症(ITP)的最新疗效:一项多中心、随机、开放标签、III期临床试验
汇报人:Menglin Li(北京大学人民医院)汇报时间:Monday, December 9, 2024: 11:15 AM汇报地点:Room 29 (San Diego Convention Center)
29
摘要号:806
标题:Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study
中文标题:Rovadicitinib治疗噬血细胞性淋巴组织细胞增生症患者的单臂、开放标签、I期研究
汇报人:王昭(北京友谊医院)
汇报时间:Monday, December 9, 2024: 3:00 PM
汇报地点:Room 6DE (San Diego Convention Center)
30
摘要号:810
标题:Pharmacological and Mechanism Study of a New RIPK1 Inhibitor Via Necroptosis to Treat Hemophagocytic Lymphohistiocytosis
中文标题:一种新型RIPK1抑制剂通过坏死性凋亡治疗噬血细胞性淋巴组织细胞增生症的药理学及机制研究
汇报人:Jinbing Zhu(四川大学华西医院)汇报时间:Monday, December 9, 2024: 4:00 PM汇报地点:Room 6DE (San Diego Convention Center)
31
摘要号:893
标题:Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study
中文标题:维奈托克联合地塞米松作为t(11;14)轻链淀粉样变性的一线治疗:一项II期前瞻性、多中心、单臂研究的初步结果
汇报人:Kaini Shen [中国医学科学院北京协和医院(北京协和医院)]汇报时间:Monday, December 9, 2024: 3:45 PM汇报地点:Seaport Ballroom EFGH (Manchester Grand Hyatt San Diego)
32
摘要号:1044
标题:A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation
中文标题:低剂量芦可替尼在同种异基因造血干细胞移植中预防移植物抗宿主病的多中心随机对照试验
汇报人:Hengwei Wu(浙江大学医学院附属第一医院骨髓移植中心)汇报时间:Monday, December 9, 2024: 5:45 PM汇报地点:Room 6B (San Diego Convention Center)
(来源:《肿瘤瞭望–血液时讯》编辑部)
声 明
凡署名原创的文章版权属《肿瘤瞭望》所有,欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议,如果该信息被用于资讯以外的目的,本站及作者不承担相关责任。